MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer

Summary: Despite much progress in targeting the MYC oncoprotein, combination treatment strategies are needed to exploit this molecular vulnerability. To this end, we interrogated transcriptome data from cancer cell lines treated with MYC inhibitors and identified HDAC5 and HDAC9, both class IIa hist...

Full description

Saved in:
Bibliographic Details
Main Authors: Jina Park, Ying-Yu Chen, Jennie J. Cao, Julia An, Ray-Whay Chiu Yen, John D. Outen, Stephen B. Baylin, Michael J. Topper
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Cell Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124725004930
Tags: Add Tag
No Tags, Be the first to tag this record!